116 related articles for article (PubMed ID: 12236939)
1. [Utility of pravastin in cardiac transplant dyslipidemia].
Martínez-Dolz L; Almenar Bonet L; Arnau Vives MA; Rueda Soriano J; Osa Sáez A; Dicenta Gisbert F; Palencia Pérez M
Rev Clin Esp; 2002 Sep; 202(9):489-91. PubMed ID: 12236939
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients.
Penson MG; Fricker FJ; Thompson JR; Harker K; Williams BJ; Kahler DA; Schowengerdt KO
J Heart Lung Transplant; 2001 Jun; 20(6):611-8. PubMed ID: 11404165
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.
Park JW; Siekmeier R; Merz M; Krell B; Harder S; März W; Seidel D; Schüler S; Gross W
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):439-50. PubMed ID: 12395976
[TBL] [Abstract][Full Text] [Related]
4. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro.
Katznelson S; Wang XM; Chia D; Ozawa M; Zhong HP; Hirata M; Terasaki PI; Kobashigawa JA
J Heart Lung Transplant; 1998 Apr; 17(4):335-40. PubMed ID: 9588577
[TBL] [Abstract][Full Text] [Related]
5. Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients.
Capone D; Stanziale P; Gentile A; Imperatore P; Pellegrino T; Basile V
Am J Nephrol; 1999; 19(3):411-5. PubMed ID: 10393380
[TBL] [Abstract][Full Text] [Related]
6. Role of statins in the management of dyslipidemia after cardiac transplant: randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin.
Magnani G; Carinci V; Magelli C; Potena L; Reggiani LB; Branzi A
J Heart Lung Transplant; 2000 Jul; 19(7):710-5. PubMed ID: 10930822
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.
Aliabadi AZ; Mahr S; Dunkler D; Grömmer M; Zimpfer D; Wolner E; Grimm M; Zuckermann AO
Transplantation; 2008 Dec; 86(12):1771-6. PubMed ID: 19104420
[TBL] [Abstract][Full Text] [Related]
8. Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin.
Imagawa DK; Dawson S; Holt CD; Kirk PS; Kaldas FM; Shackleton CR; Seu P; Rudich SM; Kinkhabwala MM; Martin P; Goldstein LI; Murray NG; Terasaki PI; Busuttil RW
Transplantation; 1996 Oct; 62(7):934-42. PubMed ID: 8878387
[TBL] [Abstract][Full Text] [Related]
9. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
[TBL] [Abstract][Full Text] [Related]
10. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment with low-dose pravastatin and fish oil in post-renal transplantation dislipidemia.
Grekas D; Kassimatis E; Makedou A; Bacharaki D; Bamichas G; Tourkantonis A
Nephron; 2001 Aug; 88(4):329-33. PubMed ID: 11474227
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
Sponseller CA; Morgan RE; Kryzhanovski VA; Campbell SE; Davidson MH
Clin Ther; 2014 Aug; 36(8):1211-22. PubMed ID: 24998014
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation.
Crespo-Leiro MG; Paniagua MJ; Marzoa R; Grille Z; Naya C; Flores X; Rodriguez JA; Mosquera V; Franco R; Castro-Beiras A
Transplant Proc; 2008 Nov; 40(9):3060-2. PubMed ID: 19010194
[TBL] [Abstract][Full Text] [Related]
15. Managing dyslipidemia in the high-risk patient.
Stein EA
Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.
Park JW; Siekmeier R; Lattke P; Merz M; Mix C; Schüler S; Jaross W
J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):351-61. PubMed ID: 11907637
[TBL] [Abstract][Full Text] [Related]
17. Combination of pravastatin and cyclosporin in transplant patients.
Christians U
Clin Pharmacokinet; 1997 Feb; 32(2):173-4. PubMed ID: 9068930
[No Abstract] [Full Text] [Related]
18. The effect of pravastatin on acute rejection after kidney transplantation--a pilot study.
Katznelson S; Wilkinson AH; Kobashigawa JA; Wang XM; Chia D; Ozawa M; Zhong HP; Hirata M; Cohen AH; Teraski PI
Transplantation; 1996 May; 61(10):1469-74. PubMed ID: 8633373
[TBL] [Abstract][Full Text] [Related]
19. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival.
Mehra MR; Uber PA; Vivekananthan K; Solis S; Scott RL; Park MH; Milani RV; Lavie CJ
J Am Coll Cardiol; 2002 Nov; 40(9):1609-14. PubMed ID: 12427413
[TBL] [Abstract][Full Text] [Related]
20. Increase or decrease of HDL-cholesterol concentrations during pravastatin treatment depending on the pre-treatment HDL cholesterol levels.
Narita Y; Kitazoe Y; Kurihara Y; Okuhara Y; Takamatsu K; Saito N; Doi Y
Eur J Clin Pharmacol; 1997; 52(6):461-3. PubMed ID: 9342581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
